A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2027

Conditions

HCCLiver Cancer

Interventions

DRUG

PM8002

PM8002 via IV infusion, Q3W

DRUG

PM1009

PM8002 via IV infusion, Q3W

DRUG

atezolizumab

atezolizumab,1200mg, via IV infusion, Q3W

DRUG

bevacizumab

bevacizumab,15mg/kg, via IV infusion, Q3W